Explore Bayer AG’s recent stock volatility, AI & CRISPR partnerships, and how these moves could reshape its oncology pipeline and long‑term growth strategy.
Market soft spot: Bayer shares dipped amid EU sell‑off, political unrest, and rising oil. The decline reflects broader macro pressure, not a core hit to the firm’s fundamentals or biotech strategy.